Leveraging ctDNA-based Molecular Response Monitoring to Accelerate Clinical Development
Time: 2:00 pm
day: Day Two Track B
Details:
- How does the integration of ctDNA as a molecular response biomarker in early clinical trials improve patient risk stratification
- Investigating case studies that demonstrate how molecular response assessment using ctDNA can predict clinical outcomes
- Harnessing ctDNA data alongside radiographic imaging for informed early Go/No Go decisions in clinical trials.
